Patients with known DNA repair gene aberrations, compared with patients without DNA repair gene aberrations, had higher median (range) PSA levels at diagnosis (33.0 [2.1-1759.0] ng/mL vs 17.5 [1.1-1530.0] ng/mL, P = .20), higher rates of de novo metastatic disease (42 [52.5%] vs 40 [40.8%], P = .10) (eTable 1 in the Supplement), and a shorter median (IQR) time from diagnosis of CRPC to start of platinum-based treatment (32.7 [11.8-80.6] months vs 52.5 [20.4-89.2] months; P = .06), although none of the differences were statistically significant. The gene discussed is KLK3; the disease is metastatic neoplasm.